VaxThera Obtains Patent for a Universal Vaccine Against COVID-19

The United States Patent and Trademark Office (USPTO) has granted our client VaxThera, a Colombian biotechnology company, a patent for its universal vaccine against the COVID-19 coronavirus. The vaccine features a mosaic protein for broad protection against various coronavirus strains and variants. This milestone marks a significant achievement for Colombia’s pharmaceutical industry, which has not produced vaccines locally since 1998.

Sterne Kessler director and founding partner, Jorge Goldstein, together with associate Kris Schroder, supported VaxThera during the patent process. Jorge commented “The only asset that a start-up biotechnology research company like VaxThera has at the beginning of its corporate life is its intellectual property. This patent protects that intellectual property in the United States market and globally values the contribution made by the company’s pioneering scientists.”